Trial Profile

A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemdomespib (Primary)
Indications Alzheimer's disease; Demyelinating disorders; Diabetic neuropathies
Focus Adverse reactions; First in man
Sponsors Reata Pharmaceuticals

Most Recent Events

01 Mar 2021 Results published in the Reata Pharmaceuticals financial media release.
27 Nov 2017 Status changed from recruiting to completed.
03 Mar 2017 According to a Reata Pharmaceuticals media release, the company plans to complete this trial and report data in the second half of 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com